Articles tagged with Cancer Patients
A team of researchers found that diffuse anaplasia (DA) subtype of Wilms tumor grows despite high DNA damage and TP53 mutation, leading to resistance to chemotherapy. The study suggests that DA histology emerges through accumulating DNA damage and CNAs, creating selection pressure for TP53 mutations.
Researchers from King's College London developed an AI model to predict brain cancer patient outcomes after radiotherapy. The model showed improved performances when trained on 10,000s of brain MRI scans and can give clinicians accurate predictions with a single routine scan, allowing for early treatment decisions.
Researchers have developed a novel virtual reality-based relaxation therapy that helps cancer patients in palliative care manage symptoms and stress better. The therapy, known as FLOW-VRT-Relaxation, combines standard-of-care relaxation techniques with immersive VR experiences to promote psychological states of flourishing.
Researchers from UPV propose using rCBV as a predictive marker to identify patients with moderately vascularized tumors who benefit most from bevacizumab treatment. This approach enhances treatment efficacy and improves clinical outcomes.
A study found that the 21-gene breast recurrence score test may underestimate chemotherapy benefits for young Black women with estrogen receptor-positive breast cancer. The researchers recommend lowering the test's cutoff point to ensure accurate treatment recommendations for all patients regardless of race or ethnicity.
Researchers have developed an AI-driven test that accurately diagnoses ovarian cancer in women clinically classified as normal, improving detection of early-stage disease. The test uses machine learning and blood metabolite information to assign a probability of disease presence or absence, offering a more clinically informative approach.
A recent study published in Lancet Microbe suggests that immunocompromised patients are at higher risk for COVID infections, but prolonged infections lasting weeks to months are uncommon. The study found that specific conditions, such as B-cell cancers and autoimmune diseases, increase the risk of prolonged infections.
Researchers discovered that cisplatin chemotherapy enhances the immune system's ability to fight bladder cancer by modulating the immune response and damaging DNA in cancer cells. This approach may lead to durable disease control in a subset of patients with metastatic bladder cancer.
Researchers report a case of a patient with EGFR L858R mutant non-small cell lung cancer (NSCLC) who experienced durable disease improvement after empirical treatment with osimertinib. The 'Lazarus effect' refers to the phenomenon where cancer appears to recur after seeming to be in remission.
Researchers developed an mRNA therapeutic that combats ovarian cancer by producing functional p53 protein, shrinking and killing tumors. The treatment is effective against metastases and has shown promise in preclinical studies.
Researchers at Penn Medicine analyzed over 400 patients treated with CAR T cell therapy and found only 16 cases of second cancers, mostly solid tumors. A single case of CAR-negative T-cell lymphoma was identified in a patient who developed a secondary lung tumor after treatment.
Researchers found that high levels of FSP1 are associated with relapse after cisplatin treatment in head and neck squamous cell carcinoma. Targeting FSP1 can attenuate tumor stemness and downregulate invasion and metastatic rates, suggesting a potential new approach for treating drug-tolerant persister cancer cells.
A Phase 3 clinical trial found that combining testosterone-blocking drugs prevents cancer spread and extends treatment time in patients with relapsed prostate cancer. The approach is more effective than single-drug treatment in delaying cancer progression.
A new study found that Black patients were more likely to choose active surveillance, while those with a strong desire for a cure or expecting longer life with treatment were less likely. Education and urologist interventions can increase active surveillance adoption among low-risk prostate cancer patients.
A new international trial investigated the safety and efficacy of sabatolimab combined with hypomethylating agents in patients with myelodysplastic neoplasms. The study found manageable side effects, but no significant improvement in response rates or progression-free survival.
This study explores the perspectives of primary care physicians (PCPs) and urologists on active surveillance (AS) care for men with low-risk prostate cancer. Key findings include the importance of patient education and clear communication among care team members to prevent loss to follow-up.
Stacyann Bailey studies how cancer treatment affects bones, hoping to prevent fractures and improve patient outcomes. Up to 50% of patients with metastatic bone disease develop fractures due to treatment, making her work crucial for their quality of life.
Researchers discovered a connection between hepatitis B and C viruses and multiple myeloma, finding that antiviral treatment can improve outcomes. The study suggests that early detection of these infections may lead to better treatment and survival rates for patients with this cancer.
A groundbreaking study identifies FAM3C as a key regulator of breast cancer progression within the tumor microenvironment. The overexpression of FAM3C promotes breast cancer cell survival and metastasis, while its depletion inhibits tumor growth in genetically engineered mouse models.
Researchers identified key characteristics associated with improved CAR T outcomes in large B cell lymphoma, including a B-cell gene expression signature and high CD19 protein expression. Patients who received axicabtagene ciloleucel had better event-free survival compared to those receiving standard therapy.
Sezáry syndrome patients face a vicious circle where cancer and treatment weaken the immune system, allowing bacteria like S. aureus to thrive. Eliminating these bacteria may make cancer cells more susceptible to anti-cancer drugs.
Researchers discuss reductive carboxylation of glutamine as a potential target in acute myeloid leukemia (AML), an aggressive cancer with poor patient outcomes. The approach aims to weaken tumor cell survival mechanisms, potentially leading to novel therapies and improved patient outcomes.
Researchers found a combination treatment involving high doses of radiation and chemotherapy to be safe and effective in treating locally advanced non-small cell lung cancer. The treatment, which includes an adaptive boost plan, showed promising results in improving progression-free survival and reducing toxic side effects.
Researchers discuss clonal hematopoiesis, a condition where cells harbor somatic mutations, and its association with aging, solid tumors, and treatment outcomes. Emerging evidence suggests that CH may play a role in cancer development and survival.
Researchers unveiled a previously unknown effect of PG545 in ovarian cancer cells, inducing DNA damage and promoting autophagic degradation of RAD51. This breakthrough could aid in selecting the most appropriate treatments for ovarian cancer patients with PARPi resistance.
A new computational model, IRMMa, predicts personalized prognosis for newly diagnosed multiple myeloma patients based on tumor genomics and treatments. The model improves on previous prognostic tools by taking into account individualized risk and distinct subtypes of the disease.
Researchers found that specific microbes in the gut reduce graft versus host disease after stem cell transplantation. Patients with low microbial metabolite risk index had better survival rates, fewer graft vs. host reactions, and reduced relapses.
A study found that patients with breast cancer are more likely to choose distant hospitals for surgery based on factors such as age, ethnicity, and living location. The investigation highlights the potential for healthcare inequalities to worsen if policies do not address these disparities.
A phase III study found that selpercatinib significantly improves cancer progression-free survival in patients with NSCLC and RET gene translocations. The therapy also demonstrated efficacy in treating intracranial lesions, a common challenge in advanced NSCLC.
The Colorado Center for Personalized Medicine has hit a major milestone of returning clinical genetic results to over 30,000 patients, making it a leader in providing personalized patient care. The center is also studying pharmacogenomics and providing results to guide drug selection and dosing.
A new study from Sylvester Comprehensive Cancer Center suggests that prophylactic treatment can significantly reduce the rate of cytokine release syndrome (CRS) in multiple myeloma patients. This approach could eliminate hospital stays and broaden access to immunotherapy treatments for more cancer patients.
A risk model based on routine blood work can identify cancer patients who are more likely to benefit from immune checkpoint inhibitors, increasing treatment efficacy and cost-effectiveness. The study found that patients in the low-risk group had a higher response rate and longer overall survival compared to those in the high-risk group.
A new study found that patients treated at community cancer centers have poorer survival rates compared to those at academic medical centers. The study analyzed data from over 20,000 patients with HPV-related oropharyngeal squamous cell cancers.
Researchers at Brigham and Women's Hospital found nearly 6,000 additional US patients could benefit from immunotherapy treatment due to mismatch repair deficiency. Next-generation sequencing revealed previously missed cases, improving patient outcomes.
Researchers at NUS Yong Loo Lin School of Medicine discovered that certain breast tumour cells sacrifice their own growth to aid other cells in resisting chemotherapy, leading to higher chances of recurrence. Disrupting this cooperation could lead to more effective treatments.
Researchers from Brazil discuss the management of refractory or relapsed classic Hodgkin lymphoma in adults, highlighting novel agents such as brentuximab vedotin and immunotherapy. The Brazilian healthcare system's constraints are also considered when making treatment decisions.
A study by the University of Sydney and University of Warwick found large gaps in evidence regarding opioid medicines for cancer pain. Non-opioid medicines, including aspirin, may be as effective as opioids for background cancer pain.
A recent review of opioid medicines for cancer pain found surprisingly large gaps in evidence regarding their true benefits. Non-steroidal anti-inflammatory drugs (NSAIDs) may be at least as effective as some opioids for background cancer pain, offering potential alternatives to reduce dependence and waning analgesia over time.
A study of 64 patients with MSI-H/dMMR metastatic colorectal cancer found that 88% had not experienced a recurrence two years after stopping immunotherapy. The progression-free survival rate was 98% at one year and 84% at three years post-treatment.
A phase II clinical trial found that psilocybin-assisted therapy significantly reduced depressive symptoms in adults with cancer and major depression. Participants who received the therapy experienced a decrease in depression severity scores, with 80% showing sustained responses to treatment.
Researchers discovered a novel therapeutic target BAMBI that suppresses immune cells, reducing the effectiveness of radiation therapy and inducing therapy resistance in cancer patients. BAMBI's expression is associated with improved survival rates, suggesting it as a promising approach to overcome radiation therapy resistance.
Scientists have introduced a new class of protease-activity sensors using gold nanoparticles equipped with peptide DNA, which can detect multiple active proteases in parallel. The method works at room temperature and does not require complicated sample preparation or elaborate instruments.
Researchers at Johns Hopkins Medicine used liquid biopsies to monitor changes in circulating tumor DNA and detect immune cell expansions, predicting patient responses to immunotherapies and detecting early signs of toxic side effects. The test showed significant associations with progression-free and overall survival.
A recent study published in JNCCN found that patients from underrepresented groups treated with first-line immunotherapy for advanced Non-Small Cell Lung Cancer (NSCLC) showed similar survival outcomes as their White counterparts. The study analyzed data from 248 patients and highlighted the need for more diverse patient representation...
A systematic review has identified 29 primary risk factors associated with long-term arm morbidities following breast cancer treatments. The main risk factors include removal of lymph nodes, high body mass index, mastectomy, radiation therapy, chemotherapy, infection, and trauma to the affected arm.
A clinical trial found that using MRI and a DCIS gene profile can guide treatment decisions for patients with low-risk ductal carcinoma in situ (DCIS). Patients who received a score lower than 39 were considered low-risk and could safely forego adjuvant radiotherapy, with similar rates of disease recurrence compared to those with high-...
Women who reduced mammography frequency three years after curative breast cancer surgery had comparable outcomes to those receiving annual screening. The Mammo-50 trial found that de-escalation did not worsen survival rates or increase recurrence, while also reducing healthcare burden and stress.
Researchers discuss recent advances in blood-based liquid biopsies for prostate cancer interrogation, highlighting key biomarkers like CTCs, ctDNA, and exosomes. The studies suggest that these approaches can aid in predicting tumor recurrence, improving treatment response, and evaluating prognosis.
Researchers at the University of Turku found that bexmarilimab therapy alters macrophage behavior to promote anti-tumor immune defense. The therapy was well-tolerated and stabilized disease progression in patients with advanced-stage cancer, inducing tumor-associated macrophage and lymphocyte activation.
Imetelstat, a telomerase inhibitor, successfully treated anaemia in MDS patients for up to one year, reducing the need for red blood cell transfusions. The drug offers a novel mechanism of action for patients with lower-risk MDS who do not respond to standard treatment.
A recent study from Drexel University's College of Nursing and Health Professions aimed to understand the challenges and supports affecting individuals with GI cancer and their caregivers when it comes to maintaining a healthy diet and avoiding malnutrition. The research highlighted the importance of creating dietary interventions that...
Researchers developed a predictive model using baseline sociodemographic and financial measures to identify patients at high risk of stopping treatment with aromatase inhibitors. The model found four demographic and financial factors associated with increased non-adherence, including younger age and lower out-of-pocket costs.
Outdated medical tools cause delayed recognition and management of adverse reactions in patients of color, leading to significant distress. A more inclusive approach is urgently needed to address structural racism in radiotherapy treatment and education.
A study published at the Radiological Society of North America annual meeting found that attending regular mammograms can lower breast cancer mortality rates by up to 72%. Women who missed a scheduled mammogram had a significantly reduced survival rate, emphasizing the importance of adherence to screening schedules.
Scientists have developed a drug-eluting hydrogel that provides sustained, pH-dependent drug co-delivery and promotes anti-tumor immune responses, reducing tumor cell proliferation and growth. The treatment shows promise in treating hepatocellular carcinoma, with enhanced efficacy compared to traditional methods.
A deep learning AI model developed using mammographic images alone accurately predicted both ductal carcinoma in situ (DCIS) and invasive carcinoma, showing no bias across multiple races. The model outperformed traditional risk models in predicting breast cancer risk, providing a more accurate and equitable assessment.
A systematic review of papers found abnormalities in brain cancer and potential treatment with licensed drugs. Genetic differences were discovered between smokers and non-smokers, suggesting personalized medicine approaches.
A new AI tool combines cancerous and non-cancerous cell patterns to predict breast cancer outcomes, allowing for more precise treatment plans. This could lead to reduced chemotherapy duration and intensity for some patients.
The University of Cincinnati is conducting a clinical trial to test the safety and effectiveness of lattice therapy, a method of delivering radiation that targets specific areas of tumors. The trial aims to enroll 37 adult patients and analyze the underlying biology of tumor and immune responses to lattice therapy radiation.
A novel contamination-detection method enables faster and safer T-cell therapy production, reducing the risk for patients and speeding up treatment. The method uses cutting-edge technology to identify harmful microorganisms within 24 hours.